Bank of New Hampshire Sells 5,284 Shares of Pfizer Inc. (NYSE:PFE)

Bank of New Hampshire trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 43.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,977 shares of the biopharmaceutical company’s stock after selling 5,284 shares during the quarter. Bank of New Hampshire’s holdings in Pfizer were worth $201,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its holdings in Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares during the period. Morgan Stanley increased its holdings in Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after buying an additional 348,628 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Pfizer by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after buying an additional 5,185,453 shares during the period. Invesco Ltd. boosted its stake in shares of Pfizer by 30.9% in the 3rd quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock valued at $797,901,000 after purchasing an additional 5,678,004 shares in the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Pfizer by 0.6% in the 3rd quarter. California Public Employees Retirement System now owns 18,380,833 shares of the biopharmaceutical company’s stock valued at $609,692,000 after purchasing an additional 101,256 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $1.00 during midday trading on Thursday, reaching $25.27. The company had a trading volume of 47,095,453 shares, compared to its average volume of 41,949,781. The company’s 50 day moving average price is $27.05 and its 200 day moving average price is $28.50. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market cap of $143.09 billion, a P/E ratio of 71.14, a P/E/G ratio of 1.19 and a beta of 0.61. Pfizer Inc. has a 52-week low of $25.23 and a 52-week high of $40.37.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.14 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.65%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is currently 466.67%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.